Clinical Trial Update: Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for E-SYNC, a CAR T cell therapy using a synNotch EGFRvIII trigger to drive anti-EphA2/IL-13Ralpha2 CAR expression in glioblastoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Glioblastoma
• Glioblastoma
• Mgmt-unmethylated Glioblastoma

Drugs mentioned

• E-SYNC CAR T cells

Snippet

Sponsor: Hideho Okada, MD, PhD | Conditions: EGFR Gene Mutation, Glioblastoma | Phase 1 | Status: RECRUITING